Holen Sie sich die Stockscreener-App
7.53
6.06%
0.43
Handel nachbörslich:
7.59
0.06
+0.80%
Eupraxia Pharmaceuticals Inc Aktie (EPRX) Neueste Nachrichten
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Earnings: Clinical Progress Overshadows Slight EPS MissLong-Term Guidance - Newser
Stifel Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Eupraxia Pharmaceuticals (EPRX) Q1 2026 Miss: What Went WrongCommunity Exit Signals - Newser
Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target - Moomoo
This SailPoint Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Benzinga
Certain Non-Voting Class B Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Stock Options of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Certain Common Shares of Eupraxia Pharmaceuticals Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. - marketscreener.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating - Investing.com
Stifel initiates Eupraxia Pharmaceuticals stock with buy rating By Investing.com - Investing.com Canada
LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating - Moomoo
EPRX SEC FilingsEupraxia Pharmac 10-K, 10-Q, 8-K Forms - Stock Titan
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results - Sahm
Manchester entities, Besser & Frank disclose EPRX holdings (EPRX) - Stock Titan
Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing - TipRanks
Eupraxia Pharmaceuticals: Well-capitalized Into 2H28 >EPRX.T - Moomoo
Eupraxia Pharmaceuticals reports first quarter 2026 financial results - marketscreener.com
Eupraxia Pharmaceuticals Q1 Loss Narrows - Moomoo
Eupraxia (NASDAQ: EPRX) funds EP-104GI trial despite higher quarterly loss - Stock Titan
Eupraxia Pharmaceuticals Says "Well-capitalized into Second Half 2028, Beyond Key Catalysts" With Over US$140M Cash - marketscreener.com
Eupraxia Pharmaceuticals Cites "Robust Response" In Highest Dose Cohort After 36 Weeks Following a Single Treatment of EP-104GI - marketscreener.com
Eupraxia Pharmaceuticals Incurred a Q1 Net Loss of US$12.7M - marketscreener.com
EPRX: Eupraxia Pharmaceuticals Inc.Interactive Chart - Zacks Investment Research
Aisling Capital Management LP's Eupraxia Pharmaceuticals Inc(EPRX) Holding History - GuruFocus
TradingKey - TradingKey
Number of shareholders of Eupraxia Pharmaceuticals, Inc. – FWB:X43 - TradingView
Eupraxia wins new (US) $15.50 target at Leede Financial - Cantech Letter
Eupraxia reports EoE trial data on inflammation and fibrosis By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Inc. - Menafn.com
Stocks in play: Eupraxia Pharmaceuticals Inc. - Barchart.com
Eupraxia Pharmaceuticals' First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia reports EoE trial data on inflammation and fibrosis - Investing.com UK
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI - TipRanks
Eupraxia Pharmaceuticals’ First Release of EoEHSS Sub Scores Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - The Manila Times
In Eupraxia’s top-dose EoE cohort, tissue scores improved >90% - Stock Titan
Eupraxia (EPRX) shows >90% EoE tissue score gains at top RESOLVE dose - Stock Titan
Eupraxia reports endoscopy score data from EoE trial By Investing.com - Investing.com Australia
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week - Investing News Network
Eupraxia reports endoscopy score data from EoE trial - Investing.com UK
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW - TipRanks
Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW) - The Manila Times
Why 20 shots matter: Eupraxia links fuller dosing to lower EoE scope scores - Stock Titan
Why Eupraxia Pharmaceuticals (EPRX) guidance matters more than actual results | Q4 2025: Below ExpectationsHold Rating - newser.com
Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co. - Moomoo
Eupraxia Pharmaceuticals' (EPRX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Eupraxia Pharmaceuticals: Tambiah to Succeed Mark Kowalski - Moomoo
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer By Investing.com - Investing.com India
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline - TipRanks
Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer - Investing News Network
Eupraxia appoints Dr. Jeymi Tambiah as chief medical officer - Investing.com UK
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):